The estimated Net Worth of Asset Management Llp Oxford is at least $12.9 Миллион dollars as of 9 October 2019. Asset Oxford owns over 699,900 units of KBL Merger IV stock worth over $660,102 and over the last 6 years Asset sold KBLM stock worth over $12,271,243.
Asset has made over 28 trades of the KBL Merger IV stock since 2019, according to the Form 4 filled with the SEC. Most recently Asset sold 699,900 units of KBLM stock worth $7,355,949 on 9 October 2019.
The largest trade Asset's ever made was selling 699,900 units of KBL Merger IV stock on 9 October 2019 worth over $7,355,949. On average, Asset trades about 62,610 units every 8 days since 2019. As of 9 October 2019 Asset still owns at least 132,285 units of KBL Merger IV stock.
You can see the complete history of Asset Oxford stock trades at the bottom of the page.
Asset's mailing address filed with the SEC is OxAM House, 6 George Street, Oxford OX1 2BW, United Kingdom.
Over the last 7 years, insiders at KBL Merger IV have traded over $12,807,331 worth of KBL Merger IV stock. The most active insiders traders include Asset Management Partners I..., Asset Management Llp Oxford и Securities Usa Llc Mizuho. On average, KBL Merger IV executives and independent directors trade stock every 52 days with the average trade being worth of $380,652. The most recent stock trade was executed by Asset Management Llp Oxford on 9 October 2019, trading 699,900 units of KBLM stock currently worth $7,355,949.
KBL Merger Corp. IV is a private equity firm specializing in acquisition, buyout, PIPES and secondaries investments. The firm seeks to invest in healthcare or the healthcare-related wellness industry. In healthcare services the firm seeks to invest in outpatient care, physician practices, behavioral health and payor services. In pharma services the firm seeks to invest in outsourced services, contract research and generics / OTC. In health IT the firm seeks to invest in EMR / HER, revnue cycle management, telemedicine and care management. In minimal reimbursement risk the firm focuses on retail healthcare, wellness and preventative care. In devices and diagnostics the firm focuses on medical devices, diagnostics, genetic testing and lab tools. The firm typically invests in firms located in the United States. The firm seeks to invest in firms with valuation between $200 million to $700 million and EBITDA between $20 million to $70 million. The firms invest in firms with enterprise value $200 million to $700 million. The firm seeks to take majority stakes. KBL Merger Corp. IV was founded in 2016 and is New York, New York with an additional office in Newark, Delaware.
KBL Merger IV executives and other stock owners filed with the SEC include: